Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06671314 · ClinicalTrials.gov registry record
Heart Failure Therapy and Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
A clinical trial of Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction, sponsored by Novartis.
- Completed
- Registry status
- 42,494
- Enrollment target
- 1
- Study location
NCT06671314: Completed study of Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction, sponsored by Novartis.
NCT06671314 is a study of Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction that has completed, run by Novartis. The registered enrollment target is 42,494 participants, above the 1,277-participant average among 42 other Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (3228% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06671314, a study of Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- 42,494 participants
- Enrollment target
- 1
- Study location
Study Summary
This was a retrospective observational cohort study using patient data from the Get With The Guideline-Heart Failure (GWTG-HF) registry linked to Medicare Fee-for-Service (FFS) claims. The main goal of the study was to compare home-time in Medicare FFS patients with heart failure with mildly reduced or preserved ejection fraction discharged with sacubitril/valsartan versus those discharged without sacubitril/valsartan.
Primary Outcome
Time spent included home-time days, hospital days, skilled nursing facility days, rehab days, other institutional days, and death days. Home-time was defined as the number of days alive and out of the hospital, skilled nursing facility or inpatient rehabilitation facility. SAC/VAL prescription status: with SAC/VAL prescription and without SAC/VAL prescription.
Conditions Studied
Study Locations (1)
New Jersey
- Novartis Pharmaceuticals - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42,494 participants |
| Start Date | 2022-06-02 |
| Est. Completion | 2022-10-31 |
What the finished NCT06671314 record still lists
NCT06671314 is an observational study that tracks outcomes without assigning an intervention. Its 42,494 participants enrollment target places it among the larger protocols in the corpus, above the 1,277-participant average among 42 other Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (3228% higher).
The record links to 2 conditions, with Heart Failure With Preserved Ejection Fraction appearing as the primary indexed condition, and to 0 interventions.
NCT06671314 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT06671314 about?
NCT06671314 is a clinical study titled "Heart Failure Therapy and Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction". This was a retrospective observational cohort study using patient data from the Get With The Guideline-Heart Failure (GWTG-HF) registry linked to Medicare Fee-for-Service (FFS) claims. The main goal of the study was to compare home-time in Medicare FFS patients with heart failure with mildly reduced...
What is the current status of trial NCT06671314?
This trial is currently completed. The enrollment target is 42,494 participants. The study started on 2022-06-02. Estimated completion is 2022-10-31.
What conditions does trial NCT06671314 study?
This clinical trial studies the following conditions: Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction.
Who is sponsoring clinical trial NCT06671314?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06671314 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure With Preserved Ejection Fraction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06671314's enrollment target sits among peer trials
42,494 1st of 42 higher than 42 of 42 other Heart Failure With Preserved Ejection Fraction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure With Preserved Ejection Fraction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Fiber Supplementation in Heart Failure With Preserved Ejection Fraction (HFpEF)
RECRUITING · NA
-
Ketogenic Diet vs Mixed Diet in Patients With Heart Failure
RECRUITING · NA
-
Matching Perfusion and Metabolic Activity in HFpEF
RECRUITING · Phase 2
-
Pilot Study Lp299v Supplementation in Chronic Heart Failure
RECRUITING · NA
-
Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction
RECRUITING · Phase 3
-
Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01255748 · 40,000 participants
Registry Study for Radiation Therapy Outcomes
- NCT04994756 · 40,000 participants
Stroke Thrombectomy and Aneurysm Registry
- NCT06768814 · 40,000 participants · NA
Overdose Recovery and Care Access (ORCA) Qualitative Stakeholder Interviews and County-level Data
- NCT07109427 · 40,000 participants · NA
Impact of an Electronic Health Record Maintenance Alert on PSA Screening Rates in a 10-Hospital Integrated Health System
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI